Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-FRa/DM21 ADC IMGN151

An antibody-drug conjugate (ADC) composed of an asymmetric, bivalent, biparatopic antibody targeting two independent epitopes of folate receptor alpha (FRa; FolRa; FOLR1) that is conjugated, via a cleavable peptide linker, to the cytotoxic maytansinoid derivative DM21, with potential antineoplastic activity. Upon administration of anti-FRa/DM21 ADC IMGN151, the antibody moiety targets and binds to FRa expressed on tumor cells. Upon cellular uptake and internalization, DM21 is released, binds to tubulin and disrupts microtubule assembly/disassembly dynamics, which results in the inhibition of both cell division and cell growth of tumor cells. FRa is a glycosylphosphatidylinositol-linked cell surface glycoprotein, that is widely expressed in certain cancers while its expression is limited in normal tissues.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-folate receptor alpha ADC IMGN151
anti-FRa ADC IMGN151
Code name:antibody-drug conjugate IMGN151
IMGN 151
IMGN-151
IMGN151
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search